Clinical Trials for Ovarian Cancer

A Phase 1, Open-Label Study of FT836, an Off-the-Shelf CAR T-Cell Therapy, With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced, refractory solid tumors (ECOG 0–1) receive an allogeneic, off‑the‑shelf iPSC‑derived CAR T product (FT836) targeting stress‑inducible MICA/MICB (engineered to reduce antigen shedding) as monotherapy or combined with trastuzumab (HER2), cetuximab (EGFR), and/or paclitaxel. Multi‑arm cohorts assess safety and preliminary activity to establish RP2D for the combination regimens.

ClinicalTrials.gov ID: NCT07216105

A Phase 1a/1b Study of NRM-823 as Monotherapy and in Combination With Immune Checkpoint Inhibition in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with refractory locally advanced or metastatic solid tumors limited to NSCLC, TNBC, HNSCC, esophageal (SCC/adenocarcinoma), gastric/GEJ adenocarcinoma, and gynecologic (cervical/endometrial/ovarian) cancers (ECOG 0–1) receive NRM-823, a bispecific T‑cell engager targeting CD3 and a novel tumor antigen, as monotherapy with dose escalation/expansion, with a cohort combining NRM-823 plus an immune checkpoint inhibitor. Primary focus is safety and RP2D determination, with preliminary antitumor activity assessment.

ClinicalTrials.gov ID: NCT07182149

First-in-human, Open-label, Multi-site, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT329 in Participants With Advanced Solid Tumors Known to Express CA19-9

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 advanced/metastatic CA19-9–expressing solid tumors (including PDAC, cholangiocarcinoma, urothelial, colorectal, gastroesophageal junction, endometrial, and epithelial ovarian cancers) that have progressed after standard therapies; includes a randomized dose-optimization component specifically for second-line or later PDAC with no remaining expected-benefit options. Treatment is IV BNT329, a CA19-9 (sialyl-Lewis A)–targeting antibody–drug conjugate delivering a topoisomerase I inhibitor payload, given q3w or (if opened) q2w, with an optional CA19-9 antibody pre-dosing strategy in one cohort.

ClinicalTrials.gov ID: NCT07186842

A Phase I Study of DS-8201a in Combination With Olaparib in HER2-Expressing Malignancies

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Enrolls adults with ECOG ≤1 and advanced metastatic/unresectable HER2-expressing or HER2-amplified solid tumors lacking effective standard options, with an expansion cohort limited to platinum-resistant high-grade serous ovarian carcinoma (progression <6 months after last platinum) with HER2 IHC 1+ and a biopsy-accessible lesion. Patients receive trastuzumab deruxtecan (HER2-targeted antibody–drug conjugate delivering a topoisomerase I inhibitor payload) IV every 21 days plus oral olaparib (PARP inhibitor) twice daily on intermittent or continuous schedules.

ClinicalTrials.gov ID: NCT04585958

A Phase 1 First-in-Human, Open-Label Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-901 as a Monotherapy and in Combination With Bevacizumab in Adult Subjects With Ovarian Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with advanced/unresectable, histologically confirmed high-grade serous ovarian, fallopian tube, or primary peritoneal carcinoma that is platinum-resistant (progression within 6 months) after standard therapies, limited to ≤5 prior lines and ≤2 regimens since becoming platinum-resistant. Patients receive IV ABBV-901 (investigational; target/mechanism not publicly specified) as monotherapy or combined with IV bevacizumab (anti-VEGF) in dose-escalation/expansion cohorts.

ClinicalTrials.gov ID: NCT07278336

A Phase 1, First-in-Human Study of MEN2501, a KIF18A Inhibitor, as Monotherapy in Participants With Platinum-Resistant Ovarian Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with histologically confirmed high-grade serous ovarian, primary peritoneal, or fallopian tube cancer that is platinum-resistant (excluding primary platinum-refractory disease). Participants receive MEN2501 monotherapy, an oral small-molecule KIF18A (mitotic kinesin) inhibitor targeting chromosome alignment/spindle dynamics, with dose escalation followed by expansion to define RP2D and assess preliminary activity.

ClinicalTrials.gov ID: NCT07226427

Phase I Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/unresectable or metastatic solid tumors that have progressed after, are intolerant to, or lack standard systemic options (ECOG 0–1; measurable disease; excluding prior B7-H3–targeted therapy, prior topoisomerase inhibitor ADCs, significant ILD/pneumonitis, uncontrolled infection, or active/untreated CNS metastases). Patients receive SYS6043, an IV q3-week B7-H3 (CD276)–targeted antibody–drug conjugate delivering a cytotoxic payload to B7-H3–expressing tumor cells, with expansion cohorts planned in ES-SCLC, HR+/HER2− breast cancer, mCRPC, and ovarian cancer.

ClinicalTrials.gov ID: NCT07424547

A Phase 1/2a Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolls adults with relapsed/refractory, locally advanced inoperable, or metastatic solid tumors (including CRPC, NSCLC/SCLC, CRC, HNSCC, ovarian/cervical/endometrial cancers, TNBC, and esophageal SCC) who have progressed after their most recent therapy and have no suitable standard option, with ECOG 0–2 and adequate organ function (measurable disease required except in CRPC; prior Lu-177–PSMA excluded for CRPC). Patients receive 177Lu-BetaBart, a lutetium-177–labeled anti–B7-H3 (CD276) monoclonal antibody delivering beta-particle radiation as systemic radioimmunotherapy in a dose-escalation/expansion design.

ClinicalTrials.gov ID: NCT07189871

Phase 1 Study to Assess the Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy Administered in Patients With Recurrent Epithelial Ovarian Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Eligible patients are adult women with recurrent/progressive advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer (non-carcinosarcoma) after ≥1 platinum regimen, appropriate for next-line single-agent therapy, ECOG 0–2, and with at least two measurable/detectable disease sites including a lesion amenable to biopsy to provide ~1 g tumor for vaccine manufacture. Participants receive an individualized inactivated autologous whole-tumor-cell vaccine (Innocell) designed to present patient-specific tumor antigens, given intradermally with CpG 1018 (TLR9 agonist adjuvant) every 2 weeks for 3 doses.

ClinicalTrials.gov ID: NCT06366490

A Phase I, Open-label, Dose Finding, Safety, Tolerability and Exploratory Trial of THEO-260 Administered Via an Intraperitoneal Route in Patients With High Grade Serous or Endometrioid Ovarian Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adult women with measurable, advanced high-grade serous or endometrioid ovarian/fallopian tube/primary peritoneal carcinoma that is platinum-resistant or platinum-refractory (ECOG 0–1, adequate organ function). Participants receive intraperitoneal THEO-260, an investigational oncolytic adenovirus that selectively replicates in tumor tissue to cause tumor cell lysis and immune activation, administered as 6 doses over ~2 weeks in sequential dose-escalation cohorts.

ClinicalTrials.gov ID: NCT07211659